30.3 Ambulatory Community-Acquired Pneumonia

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

30.3 Ambulatory Community-Acquired Pneumonia

Key Takeaways Explain This Topic AI

Community-Acquired Pneumonia (CAP) is an acute infection of pulmonary parenchyma acquired outside of healthcare settings; Streptococcus pneumoniae remains the most common bacterial etiology, followed by atypical organisms (Mycoplasma pneumoniae, Chlamydophila pneumoniae, Legionella pneumophila) and respiratory viruses.

Definitive diagnosis of CAP requires radiographic demonstration of a pulmonary infiltrate (lobar consolidation, patchy alveolar opacities, or air bronchograms) on PA and lateral chest radiography in an ambulatory patient with compatible clinical symptoms (cough, fever, dyspnea, focal crackles, dullness, egophony).

The CURB-65 score (Confusion, Uremia BUN >19 mg/dL, Respiratory rate ≥30 breaths/min, Blood pressure SBP <90 or DBP ≤60 mmHg, Age ≥65) triages site of care: a score of 0 to 1 indicates low 30-day mortality (<1.5-3%) and safe outpatient management; a score of 2 requires short inpatient admission or close observation; a score ≥3 mandates hospital admission.

Under the 2019 ATS/IDSA guidelines, empiric treatment for healthy outpatients WITHOUT comorbidities is oral amoxicillin 1 g TID (first-line) or doxycycline 100 mg BID for 5 days; macrolide monotherapy (azithromycin) is restricted strictly to areas with documented pneumococcal macrolide resistance <25% (making it generally unsuitable in the United States).

For outpatients WITH comorbidities (chronic heart, lung, liver, or renal disease, diabetes, alcoholism, malignancy, asplenia, or immunosuppression), empiric outpatient therapy requires combination therapy: a beta-lactam (amoxicillin-clavulanate 875/125 mg BID or 2000/125 mg BID, cefpodoxime, or cefuroxime) PLUS a macrolide (azithromycin) or doxycycline; OR monotherapy with a respiratory fluoroquinolone (levofloxacin 750 mg daily or moxifloxacin 400 mg daily).

Last updated: September 2026

Community-Acquired Pneumonia: Epidemiology & Microbial Etiology

Community-Acquired Pneumonia (CAP) is an acute infection of the pulmonary parenchymal tissue (alveolar spaces and interstitium) acquired outside of a hospital, inpatient facility, or long-term nursing home. CAP affects over 5 million adults annually in the United States, representing the leading cause of infectious mortality, with approximately 80% of cases managed entirely in the ambulatory outpatient setting.

Typical Bacterial Pathogens

Streptococcus pneumoniae (Pneumococcus) : Encapsulated Gram-positive lancet-shaped diplococcus. Remains the most frequent bacterial pathogen across all age groups. Classically presents with sudden onset of a single shaking chill (rigor), high fever, pleuritic chest pain, and rust-colored (prune-juice) sputum , producing dense lobar consolidation with air bronchograms on imaging.

Haemophilus influenzae : Pleomorphic Gram-negative coccobacillus. Highly prevalent in elderly patients, chronic cigarette smokers, and patients with pre-existing chronic obstructive pulmonary disease (COPD) or bronchiectasis.

Moraxella catarrhalis : Gram-negative diplococcus. Common in older adults with chronic lung disease; produces beta-lactamase in >90% of isolates.

Staphylococcus aureus : Gram-positive cocci in clusters (MSSA and MRSA). Characteristically complicates post-influenza viral infections, causing rapid cavitary necrosis, pneumatoceles, empyema, and high mortality.

Klebsiella pneumoniae : Encapsulated Gram-negative bacillus. Classically associated with severe chronic alcoholism, diabetes, and malnutrition; presents with thick, gelatinous, blood-stained "currant jelly" sputum , upper lobe cavitation, and the "bulging fissure sign" on radiography.

Pseudomonas aeruginosa : Aerobic Gram-negative rod. Encountered primarily in patients with structural lung disease (severe cystic fibrosis, bronchiectasis) or advanced COPD requiring frequent systemic corticosteroids and broad-spectrum antibiotics.

Atypical Bacterial Pathogens

"Atypical" organisms lack a rigid peptidoglycan cell wall or replicate intracellularly, rendering them intrinsically resistant to beta-lactam antibiotics (penicillins, cephalosporins) and invisible on standard sputum Gram stains.

Mycoplasma pneumoniae :

Lacks a peptidoglycan cell wall; enclosed only by a sterol-containing lipid trilaminar membrane.

Highly prevalent in young adults, college students, and military recruits in close quarters.

Clinical Features: Classic "walking pneumonia" — insidious onset of persistent dry hacking cough, low-grade fever, headache, malaise, pharyngitis, and prominent fatigue. Pulmonary examination is often deceptively normal despite extensive patchy bilateral infiltrates on radiography ("radiograph looks worse than the patient").

Extrapulmonary Complications: Bullous myringitis (hemorrhagic or serous blebs on the tympanic membrane), erythema multiforme (target lesions), Stevens-Johnson syndrome, and cold agglutinin-mediated autoimmune hemolytic anemia (elevated IgM cold agglutinins directed against erythrocyte I-antigens causing complement fixation).

Chlamydophila pneumoniae : Obligate intracellular bacterium. Insidious onset, producing pharyngitis, laryngitis, and hoarseness followed days to weeks later by mild subacute pneumonia.

Legionella pneumophila :

Fastidious Gram-negative bacillus inhabiting aquatic environments, air-conditioning cooling towers, hotel plumbing systems, hot tubs, and decorative fountains. Transmitted via inhalation of aerosolized contaminated water droplets (no person-to-person transmission).

Clinical Features (Legionnaires' Disease): Severe pneumonia characterized by:

• Very high spiking fevers (often >40.0°C / 104°F);
• Relative bradycardia (Faget sign) : Heart rate inappropriately low relative to the height of fever;
• Prominent gastrointestinal symptoms : Early watery, non-bloody diarrhea, severe nausea, abdominal cramping;
• Neurologic abnormalities: Marked confusion, lethargy, encephalopathy, headache;

Distinctive Laboratory Abnormalities: Severe hyponatremia (serum Na <130 mEq/L, mediated by SIADH and renal wasting), elevated serum hepatic transaminases (AST, ALT), hypophosphatemia, and microscopic hematuria.

Diagnostic Confirmation: Urinary Legionella antigen test (detects L. pneumophila serogroup 1, responsible for 80-90% of community cases; sensitivity 70-90%, specificity >99%); respiratory PCR.

Treatment: Highly responsive to macrolides (azithromycin) or respiratory fluoroquinolones (levofloxacin); completely unresponsive to all beta-lactams.

Viral Pathogens

Viruses account for 20% to 30% of ambulatory CAP cases, led by Influenza A and B, SARS-CoV-2, Respiratory Syncytial Virus (RSV), Parainfluenza, and Human Metapneumovirus.

Clinical Presentation & Bedside Signs of Consolidation

Symptoms : Productive or dry cough, fever, chills, dyspnea, tachypnea, anorexia, fatigue, and pleuritic chest pain (sharp, localized pain exacerbated by deep inspiration or coughing, indicating inflammatory rub of the richly innervated parietal pleura).

Atypical Presentation in Older Adults : Fever, chills, and cough are frequently absent. Elderly patients often present with acute cognitive decline, new delirium, lethargy, falls, anorexia, or worsening of baseline congestive heart failure.

Physical Examination Signs of Alveolar Consolidation PHYSICAL EXAMINATION SIGNS OF ALVEOLAR CONSOLIDATION

• Palpation Percussion Auscultation
• ┌──────────────┐ ┌──────────────┐ ┌────────────────┐
• │ INCREASED │ │ DULLNESS │ │ • LATE INSP. │
• │ TACTILE │ │ TO │ │ CRACKLES │
• │ FREMITUS │ │ PERCUSSION │ │ • BRONCHIAL │
• └──────────────┘ └──────────────┘ │ BREATH SOUNDS
• (Solid dense lung (Fluid-filled lung │ • EGOPHONY │
• conducts vocal sound replaces aerated │ • PECTORILOQUY│
• vibrations better) resonance) └────────────────┘

Tactile Fremitus : Increased tactile fremitus over the consolidated lobe. Consolidated alveolar tissue transmits low-frequency vocal acoustic vibrations ("ninety-nine") to the chest wall far more efficiently than air-filled spongy parenchyma. (Contrasts with pleural effusion or pneumothorax, where fremitus is decreased).

Percussion : Dullness to percussion over consolidated lung (replaces the resonant sound of healthy aerated lung).

Auscultation :

Late Inspiratory Crackles (Rales) : Explosive opening sounds of previously collapsed small alveoli and terminal bronchioles.

Bronchial Breath Sounds : Harsh, loud, high-pitched tubular breath sounds with a prolonged expiratory phase heard over the peripheral lung fields (where soft, quiet vesicular breath sounds normally reside).

Egophony ("E-to-A Sign") : Spoken vowel sound "E" auscultates as a high-pitched, nasal, bleating "A" through consolidated parenchyma due to acoustic filtering of higher frequencies.

Whispered Pectoriloquy : Whispered syllables ("ninety-nine" or "one-two-three") are heard distinctly and clearly through the stethoscope over the consolidated region.

Diagnostic Imaging: Standard PA & Lateral Radiography

The American Thoracic Society (ATS) and Infectious Diseases Society of America (IDSA) guidelines require radiographic confirmation of a pulmonary infiltrate to establish the diagnosis of community-acquired pneumonia and differentiate it from acute bronchitis.

Radiographic Features

Lobar Consolidation : Homogeneous water-density opacity confined within anatomic lobar or segmental margins.

Air Bronchograms : Branching, dark (radiolucent) tubular airways visualized against a background of dense white (opaque) alveolar consolidation. This pathognomonic finding confirms alveolar fluid filling while the conducting bronchi remain patent.

Patchy Interstitial / Alveolar Infiltrates : Diffuse, ill-defined opacities, frequently multifocal or bilateral, characteristic of atypical and viral pneumonias.

Complications : Radiography identifies parapneumonic pleural effusions, empyema, lung abscesses, and cavitary lesions.

Follow-Up Imaging Guidelines

Clinically Improving Patients : Routine repeat chest radiography is NOT recommended for outpatients who have clinically recovered.

Radiographic Resolution Lag : Radiographic clearance lags significantly behind clinical improvement; complete resolution of consolidation typically requires 4 to 8 weeks (and up to 12 weeks in older adults or smokers).

Indications for Follow-Up CXR at 6 to 8 Weeks :

• Age > 50 years;
• Current or former tobacco smokers;

Persistent, unresolving, or recurrent respiratory symptoms.

Clinical Rationale : To ensure complete radiographic resolution and exclude an underlying endobronchial malignancy (bronchogenic carcinoma) that presented initially as post-obstructive pneumonia.

Outpatient vs. Inpatient Triage: CURB-65 & PSI Scores

Determining the site of care (ambulatory outpatient vs. inpatient floor vs. ICU) is the most critical decision in CAP management.

The CURB-65 Decision Tool

Assigns 1 point for each of the following 5 criteria :

• C - Confusion : New mental disorientation to person, place, or time, or Abbreviated Mental Test score ≤8;
• U - Uremia : Blood Urea Nitrogen (BUN) > 19 mg/dL (> 7.0 mmol/L);
• R - Respiratory Rate : Tachypnea with RR ≥ 30 breaths/min;
• B - Blood Pressure : Hypotension with Systolic BP < 90 mmHg OR Diastolic BP ≤ 60 mmHg;

65 - Age : Patient age ≥ 65 years.

• CURB-65 Score Risk Category 30-Day Mortality Recommended Site of Care
• 0 to 1 Point Low Risk < 1.5% - 3.0% Outpatient management is safe and recommended
• 2 Points Moderate Risk ~ 9.2% Short inpatient admission or closely monitored outpatient care
• 3 Points Severe / High Risk ~ 15% - 22% Inpatient hospital admission mandatory
• 4 to 5 Points Very High Risk 25% - 40% Immediate inpatient admission; evaluate for ICU admission

Clinical Variant (CRB-65) : In outpatient clinics lacking immediate laboratory BUN access, CRB-65 (Confusion, RR ≥30, SBP <90 or DBP ≤60, Age ≥65) is utilized: Score 0 = outpatient; Score 1-2 = hospital evaluation; Score ≥3 = urgent hospitalization.

Pneumonia Severity Index (PSI / PORT Score)

A comprehensive 20-variable risk prediction tool assessing age, nursing home residence, 5 comorbidities, 5 physical examination findings, and 7 lab/imaging parameters.

Classes I and II (Score <70): Outpatient management (mortality <1%).

Class III (Score 71-90): Outpatient vs. short observation stay.

Classes IV and V (Score >90): Inpatient hospital admission.

The ATS/IDSA guidelines recommend PSI over CURB-65 due to higher diagnostic sensitivity and lower unnecessary admission rates; however, CURB-65 is widely favored in outpatient family practice for its rapid bedside calculation.

ATS/IDSA 2019 Outpatient CAP Pharmacotherapy Guidelines ATS/IDSA 2019 OUTPATIENT CAP PHARMACOTHERAPY

• Radiographically Confirmed CAP (CURB-65: 0-1)
• │
• ┌───────────────────────────┴───────────────────────────┐
• ▼ ▼
• HEALTHY HOST WITHOUT COMORBIDITIES HOST WITH COMORBIDITIES
• No chronic heart, lung, liver, or renal disease • Chronic COPD, asthma, CHF, CAD
• No diabetes, alcoholism, or malignancy • Chronic kidney disease, cirrhosis
• No asplenia or immunosuppression • Diabetes mellitus, alcoholism, asplenia
• No antibiotics in past 90 days • Active cancer, immunosuppressed host
• │ • Antibiotics in past 90 days
• ▼ │
• FIRST-LINE: ▼
• Oral Amoxicillin 1 g TID x 5d (preferred) OPTION A: COMBINATION THERAPY (Preferred)

─────────────────────────────────────────── • Beta-Lactam Component:

• ALTERNATIVES: - Amoxicillin-Clavulanate 875/125 mg BID
• Oral Doxycycline 100 mg BID x 5d (or Augmentin XR 2,000/125 mg BID)
• Oral Macrolide (Azithromycin 500mg d1, - Cefpodoxime 200 mg BID, or
• 250mg d2-5) ONLY if local pneumococcal - Cefuroxime 500 mg BID

macrolide resistance is <25% • PLUS Atypical Component:

• (UNCOMMON IN THE UNITED STATES) - Azithromycin 500mg d1, 250mg d2-5, OR
• Doxycycline 100 mg BID
• ─────────────────────────────────────────
• OPTION B: MONOTHERAPY

• Respiratory Fluoroquinolone:

• Levofloxacin 750 mg PO daily x 5d, OR
• Moxifloxacin 400 mg PO daily x 5d
• *(NEVER USE CIPROFLOXACIN)*
• 1. Healthy Outpatients WITHOUT Comorbidities

Definition : No chronic cardiopulmonary, renal, or hepatic disease; no diabetes mellitus, alcoholism, malignancy, asplenia, or immunosuppressive condition; and no systemic antimicrobial exposure within the past 90 days.

First-Line Regimen: High-Dose Amoxicillin

Amoxicillin 1 g PO three times daily (TID) for 5 days (Strong recommendation).

Clinical Rationale : Streptococcus pneumoniae is the dominant pathogen. High-dose amoxicillin achieves high alveolar epithelial lining fluid concentrations that overcome intermediate penicillin resistance in pneumococci.

Alternative Regimen: Doxycycline

Doxycycline 100 mg PO twice daily (BID) for 5 days (Conditional recommendation).

Clinical Rationale : Provides excellent coverage against S. pneumoniae , H. influenzae , and atypical organisms ( Mycoplasma , Chlamydophila ). Preferred choice for patients with severe penicillin hypersensitivity (anaphylaxis).

Conditional Regimen: Macrolide Monotherapy

Azithromycin 500 mg PO on Day 1, then 250 mg PO daily on Days 2 through 5 , OR Clarithromycin 500 mg PO BID for 5 days.

CRITICAL RESTRICTION : Macrolide monotherapy is recommended ONLY in areas where pneumococcal resistance to macrolides is documented to be < 25% !

Board Pearl : In the United States, pneumococcal macrolide resistance exceeds 40% to 50% in almost all communities (mediated by ermB ribosomal methylases and mefA efflux pumps). Consequently, azithromycin monotherapy is generally NOT recommended as empiric first-line monotherapy in the US !

2. Outpatients WITH Comorbidities

Definition : Presence of chronic heart disease (CHF, CAD), chronic lung disease (COPD, asthma, bronchiectasis), chronic liver disease (cirrhosis), chronic renal disease, diabetes mellitus, alcoholism, active malignancy, functional or anatomic asplenia, immunosuppressive conditions or medications, or recent systemic antibiotic use within 90 days.

Pathogen Profile : Expanded risk for Gram-negative bacilli ( Enterobacteriaceae , H. influenzae , M. catarrhalis ), beta-lactamase producers, and drug-resistant S. pneumoniae (DRSP).

Option A: Combination Therapy (Beta-Lactam PLUS Atypical Coverage) - PREFERRED :

Beta-Lactam Component :

Amoxicillin-Clavulanate (Augmentin) : 875/125 mg PO BID, OR high-dose Augmentin 2,000/125 mg PO extended-release BID;

OR Cephalosporins: Cefpodoxime 200 mg PO BID, OR Cefuroxime axetil 500 mg PO BID;

PLUS Atypical Component :

Macrolide : Azithromycin 500 mg Day 1, then 250 mg daily; OR

Doxycycline : 100 mg PO BID.

Option B: Monotherapy with a Respiratory Fluoroquinolone :

Levofloxacin 750 mg PO once daily for 5 days ; OR

Moxifloxacin 400 mg PO once daily for 5 days .

THE CIPROFLOXACIN TRAP : Ciprofloxacin is NOT a respiratory fluoroquinolone ! Ciprofloxacin possesses notoriously poor in vitro and in vivo activity against Streptococcus pneumoniae and must NEVER be prescribed for community-acquired pneumonia !

Fluoroquinolone Safety Warnings : Because of FDA boxed warnings regarding disabling and potentially irreversible adverse reactions (tendon rupture/Achilles tendinitis, QT prolongation with torsades de pointes, aortic dissection/rupture, severe peripheral neuropathy, CNS excitation/seizures, dysglycemia/hypoglycemic coma), respiratory fluoroquinolones are reserved for patients with severe allergies to beta-lactams or who cannot tolerate combination regimens.

Duration of Antimicrobial Therapy & Clinical Stability

Minimum Duration : Antimicrobial therapy must be continued for a minimum of 5 days .

Criteria for Discontinuation : The patient must achieve clinical stability (defined as being afebrile [temperature <37.8°C / 100°F] for at least 48 to 72 hours, heart rate <100 bpm, respiratory rate <24 breaths/min, systolic BP ≥90 mmHg, and oxygen saturation ≥92% on ambient air) before stopping antibiotics.

Routine extension of treatment to 7 to 14 days in uncomplicated ambulatory CAP provides no clinical advantage and significantly increases adverse drug events and antimicrobial resistance.

Pneumococcal Immunization Guidelines

Indications : All adults aged ≥65 years, and adults aged 19 to 64 years with high-risk underlying medical conditions (diabetes, chronic lung/heart/liver/renal disease, alcoholism, cigarette smoking, asplenia, immunocompromise).

Vaccine Regimens : A single dose of PCV20 (Prevnar 20) alone, OR a single dose of PCV15 (Vaxneuvance) followed by PPSV23 (Pneumovax 23) at least 1 year later (or ≥8 weeks later in immunocompromised patients).

Loading diagram... Algorithmic Approach to Ambulatory CAP Risk Stratification and Antimicrobial Selection